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Protocol
AbstrACt
Introduction Tuberculosis (TB) remains a significant 
public health problem in South Asia. Tobacco use increases 
the risks of TB infection and TB progression. The TB& 
Tobacco placebo-controlled randomised trial aims to 
(1) assess the effectiveness of the tobacco cessation 
medication cytisine versus placebo when combined with 
behavioural support and (2) implement tobacco cessation 
medication and behavioural support as part of general TB 
care in Bangladesh and Pakistan. This paper summarises 
the process and context evaluation protocol embedded in 
the effectiveness–implementation hybrid design.
Methods and analysis We are conducting a mixed-
methods process and context evaluation informed by an 
intervention logic model that draws on the UK Medical 
Research Council’s Process Evaluation Guidance. Our 
approach includes quantitative and qualitative data 
collection on context, recruitment, reach, dose delivered, 
dose received and fidelity. Quantitative data include patient 
characteristics, reach of recruitment among eligible patients, 
routine trial data on dose delivered and dose received, 
and a COM-B (‘capability’, ‘opportunity’, ‘motivation’ and 
‘behaviour’) questionnaire filled in by participating health 
workers. Qualitative data include semistructured interviews 
with TB health workers and patients, and with policy-makers 
at district and central levels in each country. Interviews will 
be analysed using the framework approach. The behavioural 
intervention delivery is audio recorded and assessed using 
a predefined fidelity coding index based on behavioural 
change technique taxonomy.
Ethics and dissemination The study complies with the 
guidelines of the Declaration of Helsinki. Ethics approval 
for the study and process evaluation was granted by the 
University of Leeds (qualitative components), University 
of York (trial data and fidelity assessment), Bangladesh 
Medical Research Council and Bangladesh Drug 
Administration (trial data and qualitative components) 
and Pakistan Medical Research Council (trial data and 
qualitative components). Results of this research will be 
disseminated through reports to stakeholders and peer-
reviewed publications and conference presentations.
trial registration number ISRCTN43811467; Pre-results.
IntroduCtIon
Tuberculosis (TB) is a widespread infectious 
disease caused by Mycobacterium tuberculosis, 
leading to an estimated 1.3 million deaths 
among HIV-negative persons and an esti-
mated 10.4 million new TB cases in 2016.1 The 
majority of cases occur in Sub-Saharan Africa 
and South Asia.1 2 Pulmonary TB that affects 
the lungs is the most infectious form of TB, 
and tobacco use is a highly relevant risk factor 
for it.3 The WHO estimates that at least 20% 
of global TB incidence could be attributable 
to tobacco.4 Often referred to as ‘colliding 
epidemics’ of TB and tobacco use, 15% of 
strengths and limitations of this study
 ► Strengths of the process evaluation are its design 
by a multidisciplinary team, support from national 
tuberculosis programmes, and cultural and linguistic 
adaptations of the evaluation tools to the respective 
contexts.
 ► Combining quantitative and qualitative data under 
the umbrella of the UK Medical Research Council 
process evaluation framework allows us to target 
the intervention components programme theory, 
implementation, mechanisms of impact and context.
 ► Conducting the hybrid trial and implementation 
study under real-world circumstances alerts us to 
challenges and implementation barriers that can be 
addressed in intervention scale-up.
 ► Potential limitations include the sensitivity of the 
tobacco use topic, the associated possible reluc-
tance of participants to discuss their experiences 
and challenges of truly integrating the various data 
sources in the analysis.
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the global pulmonary TB burden has been attributed 
to tobacco use.5 Tobacco use not only increases the risk 
of acquiring a TB infection, it also increases the risk of 
disease progression and worsens disease outcomes and 
mortality.3 6 Considering that in 2015, 1.1 billion people 
used a form of tobacco globally,7 and that low-income 
and middle-income countries (LMICs) have an increased 
disease burden attributable to tobacco consumption,8 
it follows that tobacco cessation strategies delivered to 
patients with TB may contribute to reduced lung disease 
burden in these countries.
While studies from high income contexts have shown 
that tobacco cessation strategies combining pharma-
cological and behavioural support methods can be 
effective,9 10 such evidence is currently lacking for LMICs 
and for patients with TB in particular. Dedicated services 
to provide cessation support to tobacco users, and the 
infrastructure to support these services, do not often exist 
in LMICs.11 Provision of cessation services as a nationwide 
initiative is therefore not currently realistic in many of 
these countries. However, implementing tobacco cessa-
tion within existing TB care is both logical and poten-
tially likely to benefit patients with TB over and above 
the general cessation benefits. In addition, few studies 
have investigated whether tobacco cessation concretely 
improves TB outcomes.12 The TB & Tobacco trial aims at 
filling this knowledge gap. Its main objectives are to inves-
tigate how tobacco cessation support can be integrated 
Figure 1 Logic model of the behavioural support intervention to quit tobacco. TB, tuberculosis.
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into national TB programmes using affordable cytisine, a 
low-cost pharmacotherapy, and to assess effectiveness of 
cytisine in these contexts.
tb &  tobacco trial
The 4-year project ‘Tobacco cessation within TB programs: A 
‘real world’ solution for countries with dual burden of disease’ 
(TB &  Tobacco) is a European Union Horizon 2020-
funded study coordinated by the University of York 
and conducted together with eight international part-
ners.i The project has two goals: first, to evaluate the 
effectiveness and cost-effectiveness of providing cytisine 
in addition to tobacco cessation behavioural support 
(effectiveness goal), and second to evaluate behavioural 
support implementation using process and context eval-
uation approaches (implementation goal). While the trial 
addresses the effectiveness goal, the intervention develop-
ment phase, evaluations of process, context, sustainability 
and scale-up meet the implementation goal. Behavioural 
support for tobacco cessation will be implemented in 
routine TB care clinics at study sites in Bangladesh and 
Pakistan. The detailed trial protocol has been submitted 
for publication.
i https://www.york.ac.uk/healthsciences/research/public-health/
projects/tb-tobacco/
The trial compares active cytisine+behavioural support 
with placebo+behavioural support. Cytisine is a low-cost 
plant-derived alkaloid that mimics nicotine by targeting 
the same brain receptors.13 While cytisine has been 
proven an effective tobacco cessation medication in 
trials in Eastern Europe and New Zealand,13 14 there 
have not yet been any clinical trials in LMIC nor for 
patients with TB who could especially profit from quit-
ting tobacco.6 Patients with TB who use tobacco will be 
randomly assigned to cytisine or placebo treatment. The 
multicountry and multisite trial has its primary outcome 
continuous abstinence at 6 months (self-reported), which 
is biochemically verified by a carbon monoxide level 
of <10 ppm and cotinine dip-stick level of <3 in urine 
(level 3=100–200 ng/mL cotinine) to detect smokeless 
tobacco use (effectiveness goal). Local partners are national 
non-governmental research organisations with extensive 
experience in tobacco control and the health systems in 
each country: The Initiative in Pakistan and ARK Founda-
tion in Bangladesh. In Pakistan, additionally the National 
Tuberculosis Control Programme (NTP) is a principal 
investigator and leads planning and hospital-based 
implementation at respective trial sites. They will employ 
research assistants who will be stationed at the study sites 
during trial recruitment and follow-up.
The TB & Tobacco trial will be carried out in Bangla-
desh and Pakistan with the aim to implement tobacco 
Table 1 Process evaluation objectives, research questions and data sources
Process evaluation objective Research questions Data sources
1. Assess implementation
 ► Recruitment
 ► Reach
 ► Dose received
 ► Dose delivered
 ► Fidelity
 ► To which degree is the intervention 
implemented as planned?
 ►Which barriers and facilitators to delivery 
as planned can be identified?
 ► Semi-structured interviews with health workers
 ► Semi-structured interviews with patients
 ► Reasons for non-participation as noted by 
health workers
 ► Quantitative trial data
 ► Audio recordings of intervention delivery 
(fidelity)
 ► Guided site observation
 ► Survey among research assistants
2. Assess mechanisms of 
impact (interaction)
 ►What are health workers’ and patients’ 
responses to the intervention (including 
their interactions with the intervention)
 ►Which, if any, improvements to the 
intervention are recommended by 
participants?
 ►What tailoring occurred to the 
intervention on the ground?
 ► Semi-structured interviews with health workers 
and patients
 ► Audio recordings of intervention delivery 
(fidelity)
 ► Research assistant updates on changes at 
facilities
 ► Survey among research assistants
 ► Guided site observation
3. Assess context of 
intervention delivery
 ►Which contextual factors may influence 
implementation?
 ►Which contextual factors may influence 
mechanisms of impact?
 ►Which contextual factors may influence 
outcomes?
 ► Guided site observation
 ► Survey among research assistants
 ► COM-B and COACH Questionnaires filled in by 
health workers
 ► Semi-structured interviews with health workers 
and patients
 ► Policy review
 ► Central and district and in-charge interviews
COACH, COntext Assessment for Community Health; COM-B, capability, opportunity, motivation and behaviour. 
 o
n
 30 April 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019878 on 30 March 2018. Downloaded from 
4 Boeckmann M, et al. BMJ Open 2018;8:e019878. doi:10.1136/bmjopen-2017-019878
Open Access 
cessation strategies (both behavioural support and 
cytisine) in standard national TB care. Seventeen sites 
in Bangladesh and 11 in Pakistan have been selected for 
participation in the trial based on the following criteria: 
geographical location within the country, TB patient care 
volume at health centre, care level (primary, secondary 
or tertiary), number of staff, conditions at location 
regarding work flows and willingness of centre leaders to 
participate in the study. Site locations vary from urban to 
rural regions, with a minimum new TB patient volume of 
224 per month on average for 8 months for Pakistan and 
91 for Bangladesh.
Trial recruitment is currently planned from July 2017 
in Bangladesh and from June 2017 in Pakistan until 
March 2018, while behavioural support implementation 
is planned long term at activated sites in both countries 
from June 2017. Our process evaluation will conclude in 
April 2019.
behavioural support intervention
Phase I of the TB & Tobacco trial developed a brief 
behavioural support intervention. The intervention was 
based on previous work of the team testing the effective-
ness of a behavioural support intervention in Pakistan15 
and on feasibility testing of a similar intervention in 
primary care in Nepal.16 It includes behavioural change 
techniques (BCTs) found effective in tobacco cessa-
tion in high-income contexts,17 18 which were selected 
through a participatory ranking process during expert 
focus group discussions. A BCT taxonomy from a Euro-
pean context was chosen as no similar taxonomy has yet 
been developed for smoking cessation in lower income 
countries. The selected taxonomy has previously been 
used successfully in a stop-smoking trial for patients with 
TB in Pakistan, the action to stop smoking in suspected 
tuberculosis (ASSIST) trial.15 19 During phase I, national 
TB programme staff and people with TB in each of the 
countries provided feedback on the prototype interven-
tion materials and processes through qualitative inter-
views and expert groups. Full details of the intervention 
materials development process, including the selected 
BCTs and messages, can be found in the project output 
report publicly available on the TB & Tobacco website.ii 
The intervention includes a flipbook containing key 
messages on managing TB and on how to quit tobacco 
use. These messages are delivered via photo images on 
the front of the slides and text for health workers on the 
back of slides and are reiterated in posters and leaflets. 
This type of flipbook is a familiar medium for health 
workers as these have previously been used in TB care, 
but had been lacking information on tobacco use. Similar 
materials have previously been used successfully in the 
ASSIST trial.15 One flipbook-based counselling session 
takes an estimated 15–20 min. The intervention is to be 
delivered once to all new TB tobacco users entering care 
at the study sites when they first receive counselling from 
a health worker, regardless of their subsequent participa-
tion in the trial.
ii https://www.york.ac.uk/healthsciences/research/public-health/
projects/tb-tobacco/achievements/.
Figure 2 Process evaluation framework (adapted from Moore et al20). COACH, COntext Assessment for Community Health; 
COM-B, capability, opportunity, motivation and behaviour. 
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The behavioural support intervention logic model 
is illustrated in figure 1. Health workers have a 2-day 
training to enable them to deliver the intervention. This 
training is interactive and focuses on the ‘soft skills’ of 
rapport building and communication skills to support 
health workers to use the materials and to provide BCT 
messages.
Importance of the process evaluation within the tb & tobacco 
project
While trial outcomes can give insights into effects of an 
intervention, effectiveness evaluations do not provide 
information on how an intervention could be repro-
duced or scaled up to additional level.20 Process eval-
uations embedded in trials help to systematically assess 
quality and delivery of an intervention, and to identify 
relationships between context, implementation and 
mechanisms of impact behind variations in outcomes.20 
Systematic process evaluations ask the questions ‘Was the 
programme carried out as planned? And if not, how was 
it carried out?’ to avoid type III errors of evaluating effects 
of inadequately implemented interventions.21 For the TB 
& Tobacco project and its aim of sustainably integrating 
tobacco cessation into TB care, generating useful infor-
mation for policy-makers regarding transferability of the 
intervention is of high importance.
Process evaluation objectives
Through assessing context, recruitment, reach, dose 
delivered, dose received and fidelity of the intervention, 
the process evaluation aims to:
1. systematically assess intervention implementation
2. identify mechanisms of impact between intervention 
and participants’ interactions with the intervention
3. assess the role of context in intervention imple-
mentation, impact, and intervention outcomes 
(table 1).22 23
MEthods And AnAlysIs
Process evaluation design and theory
The predefined TB & Tobacco process and context eval-
uation is a theory-based, multimethod evaluation guided 
predominantly by the UK Medical Research Council 
process evaluation framework.20 It is being conducted in 
addition to a randomised controlled trial which will estab-
lish cost-effectiveness of cytisine among patients with TB. 
Figure 2 illustrates how our process evaluation objectives 
and theories are linked to this framework. Within this 
overarching framework, the intervention programme 
theory based on BCTs17 informs causal assumptions of the 
intervention. Definition of implementation and its compo-
nents for the purposes of this study is in line with Linnan 
and Steckler’s21 approach, and includes context, reach, 
dose delivered, dose received and fidelity. As fidelity, also 
called adherence to the intervention, and its interaction 
with adaptations to individual patient’s needs in the field 
is the subject of much debate,22 we will further subdivide 
fidelity into content, coverage, frequency and duration, as 
described.24 Fidelity will be assessed for adherence to inter-
vention and for quality of delivery and further moderating 
effects of recruitment, context and participant responsive-
ness.25 See table 2 for data collection components sorted 
by clinical trial and behavioural support implementation.
study participants
Behavioural support will be rolled out as standard care at 
the study sites in both countries. All adult tobacco users 
Table 2 Data collection components on behavioural support implementation and cytisine trial
Cytisine (efficacy) BS (implementation)
Quantitative data collection from routine trial data
 ► Patient characteristics (age, gender, employment, tobacco 
use and nicotine dependency) from screening forms
 ► Patients’ reasons for non-participation in trial from screening 
forms
 ► Patients’ reasons for non-participation in tobacco cessation 
counselling as recorded by health workers
 ►Medication and behavioural support delivered
 ► Reach of the intervention
Qualitative data collection using SSIs with patients and health 
workers*:
 ► Behavioural support delivered
 ► Behavioural support received
 ► Contextual factors
 ►Mechanisms of impact
 ► Satisfaction with the programme
 ► Recommendations
Linking fidelity data to quit rates Audio recordings of BS sessions for intervention fidelity coded 
using a predefined coding fidelity index
Qualitative questions about cytisine and the trial as part of the 
interviews with patients and health workers*
Site selection:
 ► Observation checklist on site access and site characteristics
 ► Assessment of site selection criteria fulfilment based on reporting by local partners
Updates from research assistants on changes at sites
*Only at two case study sites per country.
BS, behavioural support; SSIs, semi-structured interviews.
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newly attending the study site clinics will be offered TB 
and tobacco cessation messages as part of their routine 
care, independently of their interest in or eligibility for 
the cytisine trial. Adult tobacco users diagnosed with 
pulmonary TB disease in the last 4 weeks and willing to 
quit tobacco, able to consent and to participate volun-
tarily are able to participate in the cytisine trial. Patients 
for whom research burden or study treatment can be 
expected to lead to adverse effects, and patients with 
contraindications for cytisine use will be excluded. Adults 
are defined according to national laws as being 15 years 
or older in Pakistan, and 18 years or older in Bangladesh. 
Participants for the interviews and fidelity assessment will 
also include those health workers who have agreed to be 
facilitators of the behavioural support intervention at 
their clinics.
Interview sampling at two case study sites per country
Aiming for in-depth understanding of the intervention 
process mechanisms, interviewing of patients and health 
workers takes place at two case study sites per country. 
These case study sites were preselected during a feasi-
bility assessment. In Bangladesh, case study sites were 
selected to represent one typical urban and one typical 
rural site with sufficient administrative support for the 
process evaluation interviews. In Pakistan, case study sites 
represent one TB-specific hospital and one tertiary care 
hospital to investigate differences in implementation 
opportunities. The different sampling approaches for 
case study sites were chosen based on contextual health 
systems differences: in Pakistan diversity between clinics 
occurs owing to organisational type, whereas differences 
between urban and rural clinics characterise the Bangla-
desh system. All health workers providing TB counselling 
at case study sites will be invited to participate in the inter-
view study and in the assessment of their experiences with 
the training provided as part of the intervention (n=2–4 
per country). Health workers will be interviewed at three 
time points during the trial in Bangladesh and Pakistan 
to assess changes over time: once in fall 2017 shortly after 
trial start, once in winter 2017/2018 and once in spring 
2018. The clinic in-charges (n=2 per country) at case 
study sites will be interviewed once after trial recruitment 
has ended in the Summer of 2018.
Among the patient collective, recruitment aims at 
capturing a range of experiences through a purposive and 
responsive strategy.26 Initial sampling for patient inter-
viewing is based on key sociodemographic characteristics 
(eg, age, gender, education level, employment status and 
literacy level). The aim is to capture a range of voices by 
interviewing patients of different ages, education levels, 
employment status and literacy level throughout the 
study. Ideally, 10 patients per case study site (n=20 per 
country) will consent to be interviewed twice, once imme-
diately after receiving the behavioural support (up to 5 
days after their first clinic visit) and once a few weeks later. 
A purposefully selected sample of TB experts among 
policy-makers at national (n=2 per country) and district 
level (n=2 per country) will be interviewed once in each 
country.
dAtA CollECtIon
A wide range of data sources will be used to generate 
understanding of the TB & Tobacco intervention and 
its delivery and implementation. Our process evaluation 
uses a mixed-methods approach to collect quantitative 
and qualitative data on all three evaluation objectives. 
Data will only be collected from consenting participants 
adhering to confidentiality and ethical practice specified 
in the ethics approval.
data sources for objective 1: to systematically assess 
intervention implementation
Our implementation evaluation targets the questions 
of actual versus planned intervention delivery and of 
barriers and facilitators to delivery as planned. The assess-
ment will include the following intervention compo-
nents: recruitment, reach, dose received, dose delivered 
and fidelity.
Characteristics of eligible and included or non-included patients
For a comparison of eligible/included versus eligible/
not included tobacco users, individual, but non-identifi-
able routine TB patient data from TB programmes of the 
selected study sites will be extracted from TB registers, 
screening logs and eligibility forms. This includes age 
and sex, and TB-related data such as pulmonary or extra 
pulmonary diagnosis, smear positive or smear negative 
test, new treatment or retreatment phase.
Reach
Routine patient data extracted from Trial Case Report 
Forms by local research assistants for the patient charac-
teristic assessment will be used to calculate the propor-
tion of included participants among all eligible patients 
for each month of the recruitment phase.
Dose delivered and dose received
Non-identifiable routine data from the trial dataset on 
study medicine and behavioural support delivered to 
patients will be extracted from the trial database.
Semi-structured interviews with health workers partici-
pating in the study at the case study sites in both countries 
will cover aspects of tobacco use context, implementa-
tion and mechanisms. Context-related questions include 
tobacco use rules at work places and the TB clinic, tobacco 
availability near the clinic and health worker routines that 
might be disrupted by delivering behavioural support. 
Topics relating to implementation and mechanisms of 
impact include acceptability and perceived effectiveness 
of the behavioural support and key BCTs, barriers and 
facilitators to the implementation of the behavioural 
support, perceived use of trainings, perceived compat-
ibility of general TB messages and specific tobacco 
cessation messages and health workers’ suggestions for 
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implementation beyond the trial (see interview guide 
template in English in online supplementary file 1).
Patient interviews will be semi-structured as well and 
conducted in a purposive sample of patients (see section 
on Interview sampling at case study sites for criteria). 
Interview guides cover contextual, implementation and 
interaction aspects. For context, information will be 
generated on, among others, tobacco habits among fami-
lies and friends, tobacco rules at patients’ work places, 
burden of TB medication and tobacco cessation regi-
mens, social support for quitting tobacco and tobacco 
availability near the clinic and patients’ houses and work 
place. Topical interview guides further address patients’ 
experience with the received behavioural support and 
specific BCTs, contextual factors, perceived usefulness of 
the leaflet, impressions of the TB health in context with 
tobacco cessation messages and patients’ relationship 
to practitioner. Regarding mechanisms of impact, inter-
view guides include questions on patients’ and health 
workers’ impressions on intervention effectiveness, 
possible changes to tobacco use culture among their 
social network, necessary adaptations to the programme, 
recommendations for future programme iterations and 
consequences of receiving or providing tobacco cessation 
will be elicited.
A sample of three to five behavioural support sessions 
from all study sites will be audio recorded with consent, 
and coded for intervention content, coverage, frequency 
and duration using a standardised fidelity coding 
index predeveloped specifically for the TB & Tobacco 
behavioural support intervention. Both early and later 
stages of the intervention will be included to observe a 
range of delivered session, and to identify learning effects 
or reasons for deviations from the intervention scripts. 
The fidelity coding index draws from previous similar 
work on quantitative measurement of fidelity19 and 
incorporates BCT contents as well as delivery quality.27 
Coding will be done by a group of bilingual researchers 
and cross-checked by the process evaluation team. The 
analysis of fidelity data will include the: (1) description 
of intervention fidelity by providers as assessed by imple-
menting the fidelity index, (2) association between inter-
vention fidelity and patient quit rates and (3) mediation 
and moderation pathways for adherence to interven-
tion content and quality of delivery. All analyses will be 
conducted by at least two researchers using SPSS,28 SAS29 
or R,30 depending on the institute.
data sources for objective 2: to identify mechanisms of 
impact between intervention and participants’ interactions 
with the intervention
Reasons for non-participation
Health workers delivering the behavioural support will 
record at regular intervals the reasons given by patients 
refusing to set a tobacco quit date as part of their coun-
selling session. Patients’ names or any other identifying 
information will not be included in the information 
collected. Local research assistants will collect these 
sheets from all sites in each country, translate into English 
and share with European research partners for analysis of 
behavioural support implementation.
Anonymised data on non-participation in the trial 
in Bangladesh and Pakistan will be extracted from the 
patient eligibility screening forms that are part of routine 
trial data.
Interviews with health workers and patients
Interview topic guides and interview procedures for 
mechanisms of impacts are included in the implementa-
tion assessment described above.
data sources for objective 3: to assess the role of context 
in intervention implementation, impact and intervention 
outcomes
Context in this study is described as factors that can either 
positively or negatively influence the delivery of tobacco 
cessation strategies in healthcare settings. The overall 
aim of the contextual evaluation is to understand the 
influence of those factors that are considered beyond the 
control of the healthcare professionals, the intervention 
and the patients, but could nonetheless potentially influ-
ence the outcomes under study.31
TB health workers’ competences and motivation to deliver tobacco 
cessation
The COACH (COntext Assessment for Community 
Health) and COM-B (‘capability’, ‘opportunity’, ‘motiva-
tion’ and ‘behaviour’) questionnaires32 33 were adapted 
to the Bangladeshi and Pakistani contexts and pretested, 
and will be administered to all health workers at all study 
sites at a minimum of three time points during the study: 
shortly after the implementation of the behavioural 
support package starts, at midpoint and at endpoint of the 
study. The COM-B scale will be completed by all health 
workers caring for patients with TB in the study sites 
at the three time points, as well as before and after any 
training. The COACH questionnaire will be completed 
by the facility managers/in-charges at each study site. 
These questionnaires will provide an overview of knowl-
edge, skills, attitudes and opinions of healthcare workers 
over the course of the study and allow for assessment of 
changes occurring over this period.
Guided observation and survey on environmental and social 
aspects of tobacco use
Local research assistants stationed at or near study sites 
in Bangladesh and Pakistan will be asked to fill in guided 
observation portfolios for each site. These will include 
field notes on access to study location, environmental 
noise, availability and privacy of counselling rooms, state 
of waiting areas, tobacco availability near clinics and 
similar items relevant to intervention delivery. Photos of 
infrastructure complete these observation portfolios.
A structured, written survey to be filled in by the 
research assistants for each site contains questions on 
tobacco regulations at the participating TB clinics, 
perceived support within clinics for tobacco cessation, 
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tobacco use at facilities, perceived barriers and facilitators 
for intervention delivery (see online supplementary file 2 
for the observation template).
Research assistant updates
To better understand routine or infrastructural changes 
that may occur during the project, research assistants 
stationed at or near study sites will be asked to update 
research teams regularly on uncommon or unexpected 
occurrences. These data will be consulted during inter-
pretation of interview data.
Interviews
All interviews conducted with health workers and patients 
for implementation assessment also cover context-related 
questions as described above. In each of the two coun-
tries, approximately five additional semi-structured inter-
views will be conducted to understand health service 
context and opportunities for scale-up of the interven-
tion: one with central level staff of the NTP, two with 
district level NTP staff and two with the case study sites 
facility managers/in-charges. Interview guides include 
financial and other resources allocated to tobacco cessa-
tion, TB care infrastructures, perceived challenges for 
patients with TB to quit tobacco, as well as for TB health 
workers to provide tobacco cessation.
dAtA AnAlysIs
Quantitative data
All quantitative data will be securely stored as electronic 
files, including anonymised routine trial data, question-
naires, anonymised routine patient data and research 
assistant surveys. Characteristics of eligible and included 
or non-included patients, reach, cytisine dose delivered 
and dose received data from the trial database will be 
analysed using descriptive statistics and correlation anal-
yses. Results will be reported stratified by gender and 
additional demographic characteristics where possible. 
COM-B and COACH questionnaires will be analysed 
using descriptive statistics: frequencies of items, statis-
tical dependence analysis and correlation analysis. 
Research assistant surveys will be analysed quantitatively 
using descriptive statistics for frequencies of statements 
regarding no smoking regulations at clinics and quali-
tatively using thematic analysis on the free text answers 
on site conditions and behavioural support processes 
observed by the research assistants.
Qualitative data
All qualitative data will be securely stored as written elec-
tronic files, including interview transcripts, observation 
memos, research assistant update notes and non-par-
ticipation descriptions. Data collection and analysis 
will occur concurrently in line with qualitative research 
quality guidelines.34 Interviews with health workers, 
patients, and policy-makers will be audio recorded with 
consent, transcribed verbatim, translated into English 
and jointly analysed by local teams and the process evalu-
ation team using NVivo Pro V.11 software.35 Before anal-
ysis, all transcripts will be pseudonymised. Interviewers 
will write field notes after interviews to generate contex-
tual knowledge and support interpretation of interview 
data. Observations on site access and surroundings as 
part of the research assistant observation will be included 
in the qualitative analyses.
Interview analyses
Using a combined deductive and inductive approach, 
a predefined coding framework based on constructs 
outlined in the Consolidated Framework for Intervention 
Research (CFIR)36 37 and in the Theoretical Domains 
Framework (TDF)38 39 will be used in data analysis while 
allowing for new codes on emerging issues.
CFIR has been proposed as an analysis framework suit-
able for complex interventions as well as for lower-income 
settings.40 The CFIR outlines ‘a comprehensive taxonomy 
of operationally defined constructs from multiple disciplinary 
domains (eg, psychology, sociology, organizational change) that 
are likely to influence implementation of complex programs’ 
(36:2). CFIR is particularly interested in those factors 
that influence implementation success and consists of 
five domains: intervention characteristics, outer setting, 
inner setting, characteristics of individuals and process.37 
However, since the behavioural support intervention 
in the TB & Tobacco project is built on BCTs,18 41 the 
CFIR alone is unlikely to capture the processes related 
to specific tobacco cessation behaviours advocated by the 
intervention. To assess these aspects, TDF that builds on 
the same BCT theories38 39 as used in intervention devel-
opment will be employed and combined with CFIR for a 
tailored framework approach.42
All results will be reported stratified by gender and 
additional sociodemographic characteristics where 
possible.
triangulation and data synthesis
As both qualitative and quantitative data are collected 
concurrently throughout the project data collection 
period, constant comparative iterative analysis allows for 
thorough integration of the individual data sources and 
findings.43 44 In practice, this means all collected data will 
be compared and contrasted to see whether contradic-
tions between data sources can be observed, or whether 
data from interviews can help make sense of observed 
implementation practice in the audio recordings or the 
quantitative routine data. The aim of such triangulation 
is to become aware of issues that were not anticipated, 
and to validate findings by looking for similarities across 
data sources.
Our process evaluation is not formative for immediate 
changes to the programme unless ethical issues require 
such immediate adaptations, but early findings will be 
reported to the project teams and may be considered 
in the design and implementation of sustainability and 
scale-up strategies after the trial.
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EthICs And dIssEMInAtIon
Tobacco use can be associated with stigma and might be a 
sensitive topic among the study target group. Gender, level 
of literacy and/or social status may influence the willing-
ness of patients and health workers to engage on the topic 
of tobacco use. The research team is aware of these issues 
and will tailor the conversations accordingly, for example, 
through building rapport with patients before broaching 
the topic of tobacco. All data collection will be preceded by 
participants’ written informed consent. Quantitative data will 
be collected by local research assistants at trial sites, anony-
mised and uploaded to the main trial database, from which 
the process evaluation team will extract only unidentifiable 
patient data. Patients will give consent to the use of their data 
as part of the overall trial consent procedure.
Interview and fidelity data require additional written 
consent, without which interviews or fidelity recordings will 
not be conducted. Provided consent forms are adaptable for 
illiterate patients and allow for signature by thumbprints, 
an approved and widespread procedure in the study coun-
tries.45–47 Interview transcripts will be pseudonymised before 
analysis. All participants will be informed that they may with-
draw from the study at any time without compromising their 
regular care at the TB clinics.
The study complies with the guidelines of the Declara-
tion of Helsinki. Results of this research are expected to 
be disseminated through reports for stakeholders and via 
scientific forums, specifically peer-reviewed publications 
and conference presentations in 2018 and 2019.
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